PMID- 15855880
OWN - NLM
STAT- MEDLINE
DCOM- 20050722
LR  - 20050427
IS  - 0172-780X (Print)
IS  - 0172-780X (Linking)
VI  - 26
IP  - 2
DP  - 2005 Apr
TI  - Association between human leukocyte antigen (HLA) and interferon- induced thyroid 
      diseases in four patients with HCV-related chronic hepatitis.
PG  - 109-12
AB  - OBJECTIVES: The interferon-alpha (IFN-alpha) therapy for HCV hepatitis may 
      exacerbate or induce underlying thyroid disorders. Besides viral factors, the 
      human leukocyte antigen (HLA) may be an independent risk factor. METHODS: We 
      evaluated fifteen patients with HCV chronic hepatitis during a period of 40 
      months. At the enrollment, all the patients were negative for thyroid disorders, 
      excluding one patient with subclinical hypothyroidism. Eleven patients received 
      IFN-alpha therapy. The HLA system was examined in every patient, evaluating 
      antigens (n=40) of locus A, B and Cw and alleles (n=19) of locus DRB1* and DQB1*. 
      The HLA system was also examined in healthy subjects (n=107) as a control group. 
      RESULTS: The HCV genotype distribution in patients was: 1b=20%, 2a=60%, 3a=20%. 
      Four IFN-treated patients presented clinical thyroid disorders, including 
      autoimmune hypothyroidism (n=2), transient thyrotoxicosis (n=1) and subacute 
      thyroiditis (n=1). The HLA susceptibility to thyroid disorders (antigen/allele 
      frequency) in the whole group of patients was not different in respect to 
      controls and normal Italian population. The patients with HCV chronic hepatitis 
      that developed thyroid diseases after IFN- treatment had a double and specific 
      association with the HLA system (Mantel-Haenszel X(c)(2)=4.706, p<0.05). 
      CONCLUSIONS: This case report suggests that HLA system examination is an 
      important and promising diagnostic aspect that may be considered in order to 
      evaluate the appearance of thyroid disorders during the IFN-alpha treatment for 
      HCV-related chronic hepatitis.
FAU - Labbadia, Giancarlo
AU  - Labbadia G
AD  - Department of Medical Therapy, Faculty of Medicine, University of Rome La 
      Sapienza, Italy.
FAU - Martocchia, Antonio
AU  - Martocchia A
FAU - Mammarella, Antonio
AU  - Mammarella A
FAU - Paoletti, Vincenzo
AU  - Paoletti V
FAU - Rocco, Antonio
AU  - Rocco A
FAU - Benvenuto, Rosalba
AU  - Benvenuto R
FAU - Antonella, Proietti
AU  - Antonella P
FAU - Rosaria, D'Urso
AU  - Rosaria D
FAU - Trabace, Simonetta
AU  - Trabace S
FAU - Musca, Antonino
AU  - Musca A
FAU - Falaschi, Paolo
AU  - Falaschi P
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Sweden
TA  - Neuro Endocrinol Lett
JT  - Neuro endocrinology letters
JID - 8008373
RN  - 0 (Genetic Markers)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Interferon-alpha)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Autoimmune Diseases/complications/*immunology
MH  - Female
MH  - Gene Frequency
MH  - Genetic Markers
MH  - Genetic Predisposition to Disease
MH  - HLA-DR Antigens/drug effects/genetics/*immunology
MH  - Hepatitis C, Chronic/complications/drug therapy/*immunology
MH  - Humans
MH  - Hypothyroidism/complications/immunology
MH  - Interferon-alpha/adverse effects/*immunology
MH  - Male
MH  - Middle Aged
MH  - Thyroid Diseases/complications/*immunology
MH  - Thyroiditis/complications/immunology
MH  - Thyrotoxicosis/complications/immunology
EDAT- 2005/04/28 09:00
MHDA- 2005/07/23 09:00
CRDT- 2005/04/28 09:00
PHST- 2005/02/14 00:00 [received]
PHST- 2005/02/25 00:00 [accepted]
PHST- 2005/04/28 09:00 [pubmed]
PHST- 2005/07/23 09:00 [medline]
PHST- 2005/04/28 09:00 [entrez]
AID - NEL260205A01 [pii]
PST - ppublish
SO  - Neuro Endocrinol Lett. 2005 Apr;26(2):109-12.